Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS

Reuters
17 Mar
March 17 (Reuters) - Travere Therapeutics Inc ::
*TRAVERE THERAPEUTICS SUBMITS SNDA TO FDA FOR APPROVAL OF FILSPARI® (SPARSENTAN) FOR THE TREATMENT OF FSGS
*TRAVERE THERAPEUTICS INC: FDA NOTIFIED COMPANY THAT REMS MONITORING FOR EMBRYO-FETAL TOXICITY IS NO LONGER NECESSARY
*TRAVERE THERAPEUTICS INC: PLANS TO SUBMIT AMENDMENT TO REMS SNDA CURRENTLY UNDER REVIEW FOR MODIFICATION OF LIVER MONITORING
*TRAVERE THERAPEUTICS INC: CONTINUES TO EXPECT A REMS MODIFICATION PDUFA TARGET ACTION DATE OF AUGUST 28

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 17-MAR-202511:01:00.21 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10